{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:33:56Z","timestamp":1773887636753,"version":"3.50.1"},"reference-count":43,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"University Hospital of La R\u00e9union","award":["AOI 2021"],"award-info":[{"award-number":["AOI 2021"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,2,20]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting up to 14% of the French children. Topical treatments are restrictive, leading patients to seek alternative options. Medical hypnosis may be a therapeutic approach, providing hypno-analgesia through comfort and soothing of the skin as well as anxiolysis by managing stress and boosting self-esteem. To date, only five studies have explored medical hypnosis in AD, showing promising results but limited by small sample sizes and lack of control arms. This study protocol describes the methodology for an initial evaluation of medical hypnosis within a therapeutic patient education (TPE) programme, called Hypno-DA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The Hypno-Atopic Dermatitis (Hypno-AD) study is a prospective, monocentric, non-blinded, parallel, cluster-randomised controlled trial conducted at the University Hospital of La Reunion, France. The study commenced on 13 August 2024 and is scheduled to conclude on 13 August 2026. The primary objective is to assess the feasibility of recruiting for a medical hypnosis programme for children with mild-to-severe AD. 32 patients (aged 8\u201317 years) will be randomly allocated in a 1:1 ratio to receive TPE sessions combined with medical hypnosis (experimental arm) or the usual TPE sessions performed for AD without medical hypnosis (control arm). The experimental arm will employ a hypnosis-based intervention, referred to as the \u2018superhero costume\u2019 technique. Reinforcement will be provided through the practice of self-hypnosis at home, guided by listening to an audio recording provided on a Universal Serial Bus (USB) key. Secondary outcomes will be assessed at 1-month, 3-month and 6-month post-randomisation. These will include compliance with the required practice of self-hypnosis at home, rate of loss of follow-ups, patient satisfaction, effectiveness of the hypnosis programme on the control of AD (ADCT) and severity of AD (Patient-Oriented SCORing Atopic Dermatitis) and the global impression parents may have concerning the changes in their child\u2019s AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethics approval was obtained from the Ile de France I Research and Institutional Ethics Committee (No. 2022-A01153-40). All methods were carried out in accordance with French law No. 2012-300 (5 March 2012) related to research involving humans as well as Good Clinical Practices (International Council for Harmonisation (ICH) version 4 of 9 November 2016, and the decision of 24 November 2006). Methods will conform to the Declaration of Helsinki. Informed oral consent from at least one legal guardian of each participant will be obtained in addition to oral consent from the child. Results will be published in an indexed peer-reviewed journal as well as presented and disseminated at scientific conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05611346\">NCT05611346<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-110921","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:55:44Z","timestamp":1773870944000},"page":"e110921","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Applying medical hypnosis in the management of atopic dermatitis in children and young adolescents: study protocol for a pilot cluster randomised controlled trial (Hypno-AD)"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct05611346","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05611346","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9613-4512","authenticated-orcid":false,"given":"Zo\u00e9","family":"Thysebaert","sequence":"first","affiliation":[{"name":"Dermatology, UCLouvain, Bruxelles, Belgium"},{"name":"Functional Unit of Paediatric Dermatology and the Atopy School, University Hospital of La Reunion, Saint-Pierre, Saint-Pierre, R\u00e9union"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Espagnon","sequence":"additional","affiliation":[{"name":"Functional Unit of Paediatric Dermatology and the Atopy School, University Hospital of La Reunion, Saint-Pierre, Saint-Pierre, R\u00e9union"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9ry","family":"Bocquet","sequence":"additional","affiliation":[{"name":"National institute of Health and Medical Research (INSERM) Centre for Clinical Investigation (CIC) 1410 Clinical Epidemiology, University Hospital of La Reunion, Saint-Denis, Saint-Denis, R\u00e9union"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4310-215X","authenticated-orcid":false,"given":"L\u00e9a","family":"Bruneau","sequence":"additional","affiliation":[{"name":"Methodological support Unit, University Hospital of La R\u00e9union, Saint-Denis, Saint-Denis, R\u00e9union"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7198-8322","authenticated-orcid":false,"given":"Juliette","family":"Miquel","sequence":"additional","affiliation":[{"name":"Functional Unit of Paediatric Dermatology and the Atopy School, University Hospital of La Reunion, Saint-Pierre, Saint-Pierre, R\u00e9union"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"2026031814552198000_16.3.e110921.1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026031814552198000_16.3.e110921.2","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2019.0025","article-title":"Association of Atopic Dermatitis With Sleep Quality in Children","volume":"173","author":"Ramirez","year":"2019","journal-title":"JAMA Pediatr"},{"key":"2026031814552198000_16.3.e110921.3","doi-asserted-by":"crossref","first-page":"11S31","DOI":"10.1016\/S0151-9638(20)31086-3","article-title":"Fardeau de la dermatite atopique chez l\u2019enfant et l\u2019adolescent","volume":"147","author":"Misery","year":"2020","journal-title":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"},{"key":"2026031814552198000_16.3.e110921.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2010.01.004"},{"key":"2026031814552198000_16.3.e110921.5","article-title":"Quality of Life and Disease Impact of Atopic Dermatitis and Psoriasis on Children and Their Families","volume":"6","author":"Na","year":"2019","journal-title":"Children (Basel)"},{"key":"2026031814552198000_16.3.e110921.6","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jaad.2016.07.002","article-title":"Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: A systematic review","volume":"75","author":"Hill","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2026031814552198000_16.3.e110921.7","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/jid.2015.337","article-title":"Association between Atopic Dermatitis and Depression in US Adults","volume":"135","author":"Yu","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2026031814552198000_16.3.e110921.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.10.041"},{"key":"2026031814552198000_16.3.e110921.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.05.003"},{"key":"2026031814552198000_16.3.e110921.10","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jamadermatol.2021.2657","article-title":"Association of Atopic Dermatitis and Mental Health Outcomes Across Childhood: A Longitudinal Cohort Study","volume":"157","author":"Kern","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2026031814552198000_16.3.e110921.11","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaad.2018.03.017","article-title":"Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis","volume":"79","author":"R\u00f8nnstad","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2026031814552198000_16.3.e110921.12","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.70"},{"key":"2026031814552198000_16.3.e110921.13","doi-asserted-by":"crossref","DOI":"10.5415\/apallergy.2021.11.e21","article-title":"Educational intervention and atopic dermatitis: impact on quality of life and treatment","volume":"11","author":"Muzzolon","year":"2021","journal-title":"Asia Pac Allergy"},{"key":"2026031814552198000_16.3.e110921.14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jdin.2021.01.001","article-title":"Therapeutic education in atopic dermatitis: A position paper from the International Eczema Council","volume":"3","author":"Eichenfield","year":"2021","journal-title":"JAAD Int"},{"key":"2026031814552198000_16.3.e110921.15","doi-asserted-by":"crossref","first-page":"e1283","DOI":"10.1111\/jdv.19269","article-title":"First update of the living European guideline (EuroGuiDerm) on atopic eczema","volume":"37","author":"Wollenberg","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026031814552198000_16.3.e110921.16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/pde.12024","article-title":"Therapeutic patient education in atopic dermatitis: worldwide experiences","volume":"30","author":"Stalder","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"2026031814552198000_16.3.e110921.17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bjd.12932","article-title":"Therapeutic patient education in atopic eczema","volume":"170 Suppl 1","author":"Barbarot","year":"2014","journal-title":"Br J Dermatol"},{"key":"2026031814552198000_16.3.e110921.18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s13555-021-00500-4","article-title":"Tolerability of and Adherence to Topical Treatments in Atopic Dermatitis: A Narrative Review","volume":"11","author":"Tier","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026031814552198000_16.3.e110921.19","doi-asserted-by":"crossref","unstructured":"Wollenberg A , Kinberger M , Arents B , et al . European Guideline (EuroGuiDerm) on atopic eczema: Living update. Bieber T, et al.J Eur Acad Dermatol Venereol. 2025;39:1537\u201366. doi:10.1111\/jdv.20639","DOI":"10.1111\/jdv.20639"},{"key":"2026031814552198000_16.3.e110921.20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjd.12645","article-title":"Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research","volume":"170","author":"Garritsen","year":"2014","journal-title":"Br J Dermatol"},{"key":"2026031814552198000_16.3.e110921.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-012-1893-3"},{"key":"2026031814552198000_16.3.e110921.22","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1468-3083.2006.02023.x","article-title":"Cyclosporin in the treatment of patients with atopic eczema \u2013 a systematic review and meta\u2010analysis","volume":"21","author":"Schmitt","year":"2007","journal-title":"Acad Dermatol Venereol"},{"key":"2026031814552198000_16.3.e110921.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.03.024"},{"key":"2026031814552198000_16.3.e110921.24","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/09546634.2019.1655137","article-title":"Atopic dermatitis epidemiology and unmet need in the United Kingdom","volume":"31","author":"Cork","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"2026031814552198000_16.3.e110921.25","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026031814552198000_16.3.e110921.26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40257-019-00478-y","article-title":"Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial","volume":"21","author":"Paller","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"2026031814552198000_16.3.e110921.27","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jaad.2020.02.060","article-title":"Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS","volume":"82","author":"Silverberg","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026031814552198000_16.3.e110921.28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2026031814552198000_16.3.e110921.29","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"The Lancet"},{"key":"2026031814552198000_16.3.e110921.30","doi-asserted-by":"crossref","unstructured":"H\u00e4user W , Hagl M , Schmierer A , et al . The Efficacy, Safety and Applications of Medical Hypnosis: A Systematic Review of Meta-analyses. Deutsches \u00c4rzteblatt International 2016. doi:10.3238\/arztebl.2016.0289","DOI":"10.3238\/arztebl.2016.0289"},{"key":"2026031814552198000_16.3.e110921.31","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1046\/j.1529-8019.2003.01620.x","article-title":"Biofeedback, cognitive-behavioral methods, and hypnosis in dermatology: is it all in your mind?","volume":"16","author":"Shenefelt","year":"2003","journal-title":"Dermatol Ther"},{"key":"2026031814552198000_16.3.e110921.32","doi-asserted-by":"publisher","DOI":"10.2466\/pms.1990.70.2.549"},{"key":"2026031814552198000_16.3.e110921.33","first-page":"817","article-title":"FPIN\u2019s Clinical Inquiries. Complementary and alternative therapies for atopic dermatitis","volume":"85","author":"Norris","year":"2012","journal-title":"Am Fam Physician"},{"key":"2026031814552198000_16.3.e110921.34","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/j.1365-2133.1995.tb00726.x","article-title":"Hypnotherapy as a treatment for atopic dermatitis in adults and children","volume":"132","author":"Stewart","year":"2006","journal-title":"Br J Dermatol"},{"key":"2026031814552198000_16.3.e110921.35","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1080\/00207144.2020.1788391","article-title":"Hypnosis in Treatment of Atopic Dermatitis: A Clinical Study","volume":"68","author":"Delaitre","year":"2020","journal-title":"Int J Clin Exp Hypn"},{"key":"2026031814552198000_16.3.e110921.36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/jicm.2022.0699","article-title":"Hypnotherapy, Intermittent Fasting, and Exercise Group Programs in Atopic Dermatitis: A Randomized Controlled Explorative Clinical Trial During the COVID-19 Pandemic","volume":"29","author":"Rotter","year":"2023","journal-title":"J Integr Complement Med"},{"key":"2026031814552198000_16.3.e110921.37","unstructured":"Gueguen J , Barry C , Hassler C , et al . Evaluation de l\u2019efficacit\u00e9 de la pratique de l\u2019hypnose 2015. Available: https:\/\/doi.org\/10.13140\/RG.2.1.2165.7448"},{"key":"2026031814552198000_16.3.e110921.38","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-10-1","article-title":"A tutorial on pilot studies: the what, why and how","volume":"10","author":"Thabane","year":"2010","journal-title":"BMC Med Res Methodol"},{"key":"2026031814552198000_16.3.e110921.39","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-10-67","article-title":"What is a pilot or feasibility study? A review of current practice and editorial policy","volume":"10","author":"Arain","year":"2010","journal-title":"BMC Med Res Methodol"},{"key":"2026031814552198000_16.3.e110921.40","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/03007995.2019.1699516","article-title":"Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT)","volume":"36","author":"Pariser","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"2026031814552198000_16.3.e110921.41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2011.02577.x"},{"key":"2026031814552198000_16.3.e110921.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2014.04.001"},{"key":"2026031814552198000_16.3.e110921.43","doi-asserted-by":"publisher","DOI":"10.1002\/pst.185"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-110921","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:55:48Z","timestamp":1773870948000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-110921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,18]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bmjopen-2025-110921"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-110921","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}